← Back to headlines
Alnylam Initiated Outperform by BMO on RNAi Pipeline Strength
BMO Capital Markets has initiated coverage of Alnylam Pharmaceuticals with an 'outperform' rating, citing the strength of its RNAi pipeline.
19 Aug, 16:02 — 19 Aug, 16:02
Sources
Showing 1 of 1 sources
